Drug Profile
SP 20103
Alternative Names: SP20103Latest Information Update: 14 Oct 2021
Price :
$50
*
At a glance
- Originator Sarfez Pharmaceuticals
- Class
- Mechanism of Action Diuretics
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Renal failure
Most Recent Events
- 14 Oct 2021 Discontinued - Phase-II for Renal failure in USA (unspecified route) (Sarfez Pharmaceuticals pipeline, October 2021)
- 23 Jan 2018 SP 20103 is still in phase II trials for Renal failure in USA (Sarfez Pharmaceuticals, January 2018)
- 07 Dec 2015 Phase-II clinical trials in Renal failure in USA (unspecified route) prior to December 2015